ROCKVILLE, Md., May 5, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced the presentation of pre-clinical data on MGD010, a bi-specific Dual-Affinity Re-targeting (DART®) protein, demonstrating its ability to inhibit B-cell activation without B-cell depletion, which could provide a novel treatment option for patients with autoimmune disorders. MGD010 also was shown to inhibit the development of graft-versus-host disease in a humanized murine model, a system amenable to ascertain the activity of immunomodulatory intervention. These data were presented at IMMUNOLOGY 2014, the American Association of Immunologists' Annual Meeting, in Pittsburgh, PA.
Help employers find you! Check out all the jobs and post your resume.
